Related Experiment Video
Updated: Jun 14, 2026

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis
Published on: October 27, 2023
Comment on "Study on the association between Mettl3-modified Piezo1 in CD4+ T cells and inflammatory response in
Xia Qu1, Chunlian Li1, Dujiang Yang1
1Department of orthopedics, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, NO.182, Chunhui Road, Longmatan District, Luzhou, Sichuan Province 646000, PR China.
Abstract:
We read with interest the recent article by Ren et al. on METTL3-mediated m6A modification of Piezo1 in CD4+ T cells and inflammatory responses in ankylosing spondylitis (AS). The findings are intriguing, but several aspects limit the strength of the proposed pathogenic and diagnostic interpretation. The study relied on peripheral blood CD4+ T cells, whereas AS pathobiology is shaped by tissue-proximal immune responses at the enthesis and, importantly, within the synovial compartment. Bulk CD4+ T-cell analysis also overlooks the marked heterogeneity of both CD4+ and CD8+ T-cell states now recognized in spondyloarthritis. In addition, m6A enrichment on Piezo1 transcripts does not by itself establish direct METTL3-dependent regulation without higher-resolution mapping and functional rescue experiments. Finally, the reported high diagnostic performance of peripheral Piezo1 should be interpreted cautiously because strong discrimination may reflect systemic inflammation or shifts in circulating immune-cell composition rather than an AS-specific mechanism. Overall, the work is hypothesis-generating, but tissue-relevant validation and more rigorous mechanistic studies are needed before the METTL3-Piezo1 axis can be considered a defined pathogenic or biomarker pathway in AS.
Insights
The study on METTL3, Piezo1, and ankylosing spondylitis (AS) offers intriguing insights but requires further validation. Tissue-specific studies are needed to confirm the role of this pathway in AS pathogenesis and diagnosis.
Area of Science:
- Immunology
- Molecular Biology
- Rheumatology
Background:
- Ankylosing spondylitis (AS) pathogenesis involves complex immune responses.
- The methyltransferase-like 3 (METTL3)-mediated m6A modification of Piezo1 in CD4+ T cells has been proposed in AS.
- Current understanding relies on peripheral blood T cells, potentially missing tissue-specific mechanisms.
Purpose of the Study:
- To critically evaluate the proposed role of METTL3-Piezo1 axis in ankylosing spondylitis (AS).
- To assess the pathogenic and diagnostic implications of METTL3-mediated m6A modification of Piezo1 in CD4+ T cells.
- To highlight the need for tissue-specific validation and mechanistic studies in AS.
Main Methods:
- Review and critical analysis of existing data on METTL3, Piezo1, and CD4+ T cells in AS.
- Comparison of peripheral blood findings with known enthesis and synovial pathobiology in AS.
- Assessment of the limitations of bulk T-cell analysis and diagnostic performance metrics.
Main Results:
- The study by Ren et al. suggests METTL3-mediated m6A modification of Piezo1 in CD4+ T cells.
- Peripheral blood analysis may not fully represent AS pathobiology occurring at tissue sites.
- The diagnostic utility of peripheral Piezo1 requires cautious interpretation due to potential confounding factors.
Conclusions:
- The proposed METTL3-Piezo1 axis in AS requires further investigation with tissue-relevant models.
- Mechanistic studies and functional rescue experiments are essential to confirm direct METTL3 regulation.
- More rigorous validation is needed before this pathway can be established as pathogenic or a diagnostic biomarker in AS.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
The JAK-STAT Signaling Pathway